SEC Comment Letter 0000000000-24-013301 to Lyell Immunopharma, Inc. (LYEL)
Lyell Immunopharma, Inc.
Date: Dec. 3, 2024 · CIK: 0001806952 · Accession: 0000000000-24-013301
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283533
Letter
December 3, 2024 Lynn Seely, M.D. President and Chief Executive Officer Lyell Immunopharma, Inc. 201 Haskins Way South San Francisco, California 94080 Re:Lyell Immunopharma, Inc. Registration Statement on Form S-3 Filed November 29, 2024 File No. 333-283533 Dear Lynn Seely M.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Thomas Greenberg, Esq.
Show Raw Text
December 3, 2024
Lynn Seely, M.D.
President and Chief Executive Officer
Lyell Immunopharma, Inc.
201 Haskins Way
South San Francisco, California 94080
Re:Lyell Immunopharma, Inc.
Registration Statement on Form S-3
Filed November 29, 2024
File No. 333-283533
Dear Lynn Seely M.D.:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Thomas Greenberg, Esq.